top | item 38401302 (no title) mx20 | 2 years ago Goldman Sachs Analyst thinks otherwise. The company behind the Hepatitis C cure seems to also not doing well with monetizing their cure. There are also countries like Brazil that just suspended the patent.https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patie... discuss order hn newest No comments yet.
No comments yet.